Buy Zyprexa (Olanzapine)

Strongly and specifically slows down the reuptake of serotonin by neurons, thereby increasing its concentration in the synapse and enhancing its action; while having little effect on the reuptake of dopamine and norepinephrine. According to the antidepressant effect, indications for use are similar to imipramine, amitriptyline, but are better tolerated, since it has a significantly lower anticholinergic activity.

• Treatment of exacerbations;
• maintenance and long-term anti-relapse therapy of schizophrenia and other psychotic disorders with severe productive (including delusions, hallucinations, automatism) and / or negative (including emotional flattening, decreased social activity, impoverishment of speech) symptoms, as well as with concomitant affective disorders;
• treatment of acute manic or mixed seizures in bipolar affective disorder;
• can be used to treat stimulant psychosis.

• Drowsiness,
• dizziness,
• akathisia,
• hyperlactinemia,
• weight gain,
• peripheral edema,
• orthostatic hypotension,
• dry mouth,
• obstipation,
• estrapyramidal disorders,
• neuroleptic malignant syndrome,
• cholestatic jaundice,
• transient leukopenia,
• eosinophilia,
• transient increase in transaminase activity,
• skin allergic reactions.

Contraindications:

• Liver dysfunction,
• epilepsy,
• myelosuppression,
• prostatic hypertrophy,
• paralytic ileus,
• childhood and adolescence (up to 18 years),
• low leukocyte count,
• bone marrow suppression,
• myeloproliferative diseases,
• hypereosinophilic syndrome,
• hypersensitivity to the drug,
• severe CNS depression,
• coma.

With caution:

• Parkinson's disease,
• diabetes mellitus,
• concomitant use of drugs that lengthen the QT interval,
• renal failure,
• angle-closure glaucoma,
• seizures (history),
• pregnancy,
• lactation.

Zyprexa can be taken with or without food. In schizophrenia and similar psychotic disorders, the recommended initial dose of the drug is 10 mg 1 time a day. The range of therapeutic doses is 5-20 mg a day. The daily dose must be selected individually depending on the clinical condition of the patient. Increasing the dose above the standard (10 mg a day) is best done after an appropriate clinical examination of the patient.

In acute mania and in bipolar disorder, the initial dose of the drug is 15 mg 1 time a day. Therapeutic doses of olanzapine in this case range from 5-20 mg a day. The daily dose must be selected individually depending on the clinical condition of the patient. Increasing the dose above the standard dose of 15 mg a day is recommended only after an appropriate clinical examination of the patient. The dose should be increased gradually, at intervals of at least 24 hours.

Elderly patients, as well as in severe renal insufficiency or insufficiency of liver function of moderate severity, the drug is prescribed at an initial dose of 5 mg a day.

Drowsiness at the beginning of treatment develops often, so the drug is best taken at night.

A reduction in the initial dose is recommended for patients with a combination of factors (female patients, senile age, non-smokers) that may slow down the metabolism of olanzapine.

Do not drink alcohol during the course of taking the drug. Enhances the inhibitory effect on the central nervous system of ethanol. Olanzapine also removes the effect of levodopa drugs. Carbamazepine accelerates the clearance of olanzapine.

Given the nature of the action of olanzapine on the central nervous system, it should be used with caution in combination with other centrally acting drugs.

You can buy Zyprexa (Olanzapine) from our website absolutely legally.

Delivery is carried out to all countries in the world, which do not have an official ban on receiving and sending mail (mainly island countries).

We guarantee that you will receive your parcel with Zyprexa (Olanzapine) without any problems at customs (we have our own delivery channels to countries with strict customs).

We guarantee a refund if your package has not been delivered to you for any reason, according to PayPal protection policy.

Due to Quarantine, delivery time may increase slightly, but still delivery remains within reasonable limits and does not exceed the delivery time during Christmas sales.

There is no prescription required!

You can legally buy Zyprexa (Olanzapine)  our website without prescription! 

Metabolic and endocrine disorders

Olanzapine has the highest risk of obesity and metabolic disorders compared to other antipsychotics. In patients taking olanzapine 15 mg per day, after a year of therapy, body weight increases by an average of 11.8 kg. An increase in weight during treatment with this drug is noted up to 12% of the initial weight of patients. Weight gain can be up to 20-45 kg.

The consequences of obesity and metabolic disorders caused by antipsychotics seem to be no different from the consequences of obesity caused by any other causes, that is, they include an increased risk of coronary heart disease, arterial hypertension, cancer, diabetes mellitus, osteoarthritis, sleep apnea , cholelithiasis, myocardial infarction and stroke. The use of olanzapine statistically significantly increases the risk of developing diabetes by 6 times.

The metabolic disturbances mentioned above are caused by olanzapine not only in patients with mental disorders, but also in mentally healthy individuals. Studies have also shown that olanzapine reduces insulin sensitivity in healthy men after eight or ten days of use.

Diabetic ketoacidosis, a relatively rare and extremely dangerous complication of diabetes, can also be caused by olanzapine. Cases have been repeatedly noted when diabetic ketoacidosis developed suddenly, in the absence of previously diagnosed diabetes. The possibility of diabetic ketoacidosis must always be kept in mind: its mental manifestations are easily confused with the symptoms of schizophrenia.

At the beginning of treatment, especially when choosing a dosage, observation is necessary: ​​

• extrapyramidal side effects,
• orthostatic hypotension and reflex tachycardia,
• drowsiness,
• weight gain,
• hyperglycemia and hyperlipoproteinemia are possible.

The risk of orthostatic hypotension is increased when olanzapine is taken concomitantly with benzodiazepines. Drowsiness at the beginning of treatment develops often, so the drug is best taken at night.

Due to the possibility of developing agranulocytosis, it is desirable to conduct weekly blood monitoring during the first 18 weeks of therapy in patients taking olanzapine, and then monthly.

When initially prescribing olanzapine, it is necessary to assess the likelihood of a patient gaining weight, taking into account his body mass index, history, general clinical feeling of a tendency to be overweight. When observing a patient taking olanzapine, it is important to consider the basic principle of weight gain control: a seven percent increase in body weight from the initial body weight is an absolute contraindication to further use of the drug.

To prevent the development of life-threatening conditions associated with diabetes (acidosis and coma), early recognition and treatment of developing diabetes is necessary. Psychiatrists in therapy with olanzapine should be alert to symptoms of diabetes such as weight loss, drowsiness, thirst, polyuria, and, if necessary, provide their patient with an endocrinologist's consultation.

Olanzapine can also cause the development of neuroleptic malignant syndrome, a potentially fatal symptom complex, the clinical manifestations of which include:

• a significant increase in body temperature,
• muscle rigidity,
• changes in mental status and autonomic disorders (unstable pulse or blood pressure, tachycardia, cardiac arrhythmia, increased sweating).

Additional signs may include an increase in CPK levels, myoglobinuria (rhabdomyolysis), and acute renal failure. Clinical manifestations of neuroleptic malignant syndrome or a significant increase in body temperature without other symptoms of this syndrome require the abolition of all antipsychotics, including olanzapine.

In comparative studies lasting more than 6 weeks, treatment with olanzapine was sometimes accompanied by the development of tardive dyskinesia (an irreversible neurological side effect). With the development of signs of tardive dyskinesia, it is recommended to reduce the dose or stop olanzapine. Symptoms of tardive dyskinesia may increase or begin after discontinuation of the drug.

With extreme caution, the drug should be used with an increase in the activity of AST and ALT in patients with insufficiency of liver function, a limited functional reserve of the liver, or in patients receiving treatment with potentially hepatotoxic drugs. In the event of an increase in AST and / or ALT activity during treatment with olanzapine, careful monitoring of the patient and, if necessary, dose reduction is required.

Olanzapine should be used with caution in patients with a history of seizures or those exposed to factors that lower the seizure threshold. Seizures have rarely been observed in these patients treated with olanzapine.

Under in vitro conditions, olanzapine exhibits dopamine antagonism and, like other antipsychotics, inhibits the action of levodopa and dopamine agonists.

Withdrawal of olanzapine may result in cholinergic withdrawal effects, including flu-like symptoms, insomnia, agitation, confusion, restlessness, anxiety, and extrapyramidal disorders. To prevent the cholinergic effects of withdrawal, a gradual decrease in the dose of the drug is recommended (and, if it is planned to switch to another antipsychotic, a gradual increase in the doses of this antipsychotic), with the development of withdrawal symptoms, a “step back” to the previous dose of the drug being withdrawn, and its slower withdrawal, in if necessary, the appointment of correctors and benzodiazepines.